Paul Hastings Advised Keensight Capital in the Combination of Biovian & 3P Biopharmaceuticals to Create 3PBIOVIAN
February 06, 2024
February 06, 2024
LOS ANGELES, California, Feb. 6 -- Paul Hastings, a law firm, issued the following news:
Paul Hastings (Europe) LLP advised Keensight Capital in the combination of Biovian and 3P Biopharmaceuticals, two leading biologics Contract Development and Manufacturing Organizations (CDMOs), to establish 3PBIOVIAN, a new pan-european leader in their field.
Corporate partner Olivier Deren led the Paul Hastings team, which also included partner Allard de Waal, of counsel Charlotte . . .
Paul Hastings (Europe) LLP advised Keensight Capital in the combination of Biovian and 3P Biopharmaceuticals, two leading biologics Contract Development and Manufacturing Organizations (CDMOs), to establish 3PBIOVIAN, a new pan-european leader in their field.
Corporate partner Olivier Deren led the Paul Hastings team, which also included partner Allard de Waal, of counsel Charlotte . . .